We carefully select promising preclinical candidates and then work to achieve clinical proof of concept and create molecules on the cusp of becoming a drug. Here’s how we do it:
OnCusp’s global approach allows it to effectively leverage regional industry strengths. The United States and Europe have some of the world’s most innovative biotechs, top Phase 1 clinical trial sites, and the largest drug markets. Australia has fast first-in-human testing opportunities, and China has abundant funding, a large patient pool, and an efficient preclinical CRO network.
The OnCusp founders have deep, highly-credentialed experience designing innovative clinical development plans and executing rigorous clinical trials, with specific expertise in areas of particular interest to OnCusp, including novel bispecific antibodies, antibody-drug conjugates, and innovative small molecules.
OnCusp founders are veterans in global oncology drug research, development, and commercialization, and deal-making. They have built an extensive professional network within the global oncology community. This enables the company to create win-win licensing partnerships for the most promising assets and then license out proven therapies to their global pharmaceutical network.
Modality / MOA
CUSP06 is an antibody drug-conjugate (ADC) targeting a protein overexpressed in several common advanced solid tumors. This program is currently in IND-enabling studies.
CUSP03 is a small molecule inhibitor to an RNA modifying enzyme that plays a critical role in driving large subsets of a hematologic malignancy, as well as a potential role in multiple solid tumors. This program is in lead optimization stage.
CUSP02 is a novel bispecific antibody that is designed to have important anti-tumor, immune-targeting and anti-angiogenic properties. This program is currently in early discovery.
Swipe To View